Let's turn to Hims and Hers health now gaining on new expansion plans. Brandon Gomez spoke exclusively with the company's CEO. Brandon, >> hey Mike.Yeah, look, Hims and Hers has been on a sprint globally since the start of 2025. In the beginning of the year, it was in the US and the UK while it's ending the year in Germany, Spain, France, Ireland, and now Canada. The teleahalth platform completing an allcash acquisition of live well.Now that's a Canadian digital health provider known for, you guessed it, we ...

Core Insights - The weight loss therapy market is rapidly growing, with leading drugs like Wegovy and Zepbound gaining significant sales traction [1] - Pfizer has faced multiple setbacks in its attempts to enter the weight loss market, particularly with its candidates danuglipron and lotiglipron [2][3][5] Group 1: Pfizer's Weight Loss Drug Development - Pfizer discontinued lotiglipron after phase 1 studies due to potential liver issues [3] - The danuglipron program faced challenges, with a twice-daily version showing efficacy but high side effects, leading to its abandonment [4] - Pfizer scrapped the danuglipron project entirely after a phase 2 study indicated liver injury in a patient, marking a significant setback [5] Group 2: Future Prospects and Other Opportunities - Despite setbacks in the weight loss market, Pfizer is not exiting this area and will pursue other therapeutic options [6] - Pfizer's oncology market prospects are more promising, bolstered by the acquisition of Seagen for $43 billion, enhancing its cancer treatment capabilities [7][8] - Pfizer reported a 7% year-over-year revenue increase to $63.6 billion and a 69% rise in adjusted earnings per share to $3.11 [9] Group 3: Investment Considerations - Pfizer's strong financial performance and deep pipeline make it an attractive option for investors, despite recent challenges in the weight loss sector [10] - The stock offers a forward yield of 7.8%, with a 54% increase in dividends over the past decade, appealing to dividend-seeking investors [9]